Mode
Text Size
Log in / Sign up
Phase 4 N=102 Randomized Single-blind Prevention

Electrophysiologically Guided PAcing Site Selection Study

Sinus Arrhythmia · Atrial Fibrillation

Enrolled (actual)
102
Serious AEs
3.1%
Results posted
Nov 2013
Primary outcome: Primary: Number of Patients With Persistent Atrial Fibrillation (AF) After a Mean Follow-up of 15±7 Months: Comparison Between IAS and RAA Pacing in the Study Group — 2; 2; 9; 2 Number of patients with persistent AF — p=0.047

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
IAS pacing - study group (Procedure); IAS pacing control group (Procedure); Pacing RAA study group (Procedure); Pacing RAA control group (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic BRC
Primary completion
Dec 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Persistent Atrial Fibrillation (AF) After a Mean Follow-up of 15±7 Months: Comparison Between IAS and RAA Pacing in the Study Group
2; 2; 9; 2 0.047 sig
SECONDARY
Number of Persistent Atrial Fibrillation (AF) Episodes: Comparison Between All Groups
SECONDARY
Number of Patients With Permanent Atrial Fibrillation (AF)
SECONDARY
Symptom Scale Questionnaire: Comparison Between All Groups
SECONDARY
Number of Cardioversion: Comparison Between All Groups
SECONDARY
Heart Failure: Comparison Between All Groups
SECONDARY
Time to First Persistent Episode of Atrial Fibrillation (AF)
SECONDARY
Number of Episodes/Day
SECONDARY
AF Burden
SECONDARY
Ventricular Pacing Percentage

Summary

This study is a long-term, prospective, and controlled evaluation of the incidence of persistent atrial fibrillation (AF) in patients with severe intra-right atrial conduction delay paced with preventive algorithms at the interatrial septum (IAS) versus right atrial appendage (RAA).

Eligibility Criteria

Inclusion Criteria

  • Symptomatic sinus node dysfunction
  • More than 18 years old
  • Signed informed consent

Exclusion Criteria

  • Less than 18 years old
  • Pregnancy
  • Anamnestic transient ischemic attack (TIA) or stroke
  • Neoplastic or any other severe disease reducing life expectancy
  • Heart surgery in the last 3 months
  • Left atrial diameter > 55mm, determined in the parasternal long-axis view (during either sinus rhythm or atrial fibrillation)
  • Participation in other studies
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00239226). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search